Stay updated with breaking news from Neuronetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) Director Robert Cascella acquired 50,000 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were bought at an average cost of $2.05 per share, with a total value of $102,500.00. Following the completion of the transaction, the director now directly owns 244,098 shares […]
Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) Director Robert Cascella bought 50,000 shares of Neuronetics stock in a transaction on Thursday, June 6th. The stock was acquired at an average price of $2.05 per share, with a total value of $102,500.00. Following the completion of the purchase, the director now directly owns 244,098 shares of […]
Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 18,000 shares, a decline of 69.1% from the April 30th total of 58,300 shares. Based on an average daily trading volume, of 176,600 shares, the days-to-cover ratio […]
MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
Humana, a health insurance provider, has become the first commercial payer to cover TMS Therapy for adolescent depression.